Tolazamide is a first generation sulfonylurea that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2; IC50 = 4.2 µM in HEK293 cells transfected with the human receptor).

Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).

The first small-molecule inhibitor of renal outer medullary potassium channel (ROMK, Kir1.1) and Kir7.1 with IC50 of 294 nM for ROMK.

Tebanicline hydrochloride (ABT594 hydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to α4β2 neuronal nAChRs with a Ki of 37 pM.

SYM2206 is a novel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 μM ).

SRI-31142 (SRI31142) is a novel potent, putative allosteric dopamine transporter (DAT) inhibitor with Ki of 1.9 nM..

Sodium Channel inhibitor1, one of 3-Oxoisoindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.

SN 2 is a novel and potent small molecule activator of TRPML3 with EC50 of 1.13 uM.

Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.

Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM For AMPA, kainate and NMDA receptors respectively). Neuroprotective.

SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

SDZ 220-581 Hcl is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

S44819 (S 44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2).

RPR260243 was the first reported hERG channel activator.

Ro 25-6981 is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit.

Pyr6 is a selective inhibitor of TRPC3 with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).

Procaine is a benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses.

Piracetam is a cyclic derivative of the neurotransmitter ã-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.

Pilsicainide hydrochloride is a selective Na+ channel blocker (IC30 values are 9 and 60 μM for inward Na+ and Ca2+ currents respectively). Shows antiarrhythmic effects in vivo. Orally active.

Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer.

PF-4778574 (PF4778574) is a brain penetrant, positive allosteric modulator (potentiator) of AMPA receptor with Ki of 85 nM, increases S-AMPA-evoked responses in rat primary cortical neurons with EC50 of 45-919 nM.

PF-06678419 (PF06678419) is a potent, selective inhibitor of the Na+/citrate transporter NaCT (SLC13A5) that shows inhibition of citrate uptake in the HEKNaCT cells with IC50 of 0.44 uM.

PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM.

PF 03716556 is a potent, and selective acid pump (H+,K+ ATPase) antagonist, with pIC50 value of 6.009.

Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders.

PAC-14028 is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist.

Oxcarbazepine inhibits the binding of [3H]BTX to sodium channels with IC50 of 160 μM and also inhibits the influx of 22Na+ into rat brain synaptosomes with IC50 about 100 μM.

Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, showsthe potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis..